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Abstract
Background:  Cytotoxic T lymphocytes play a crucial role in the immunological control of
microbial infections and in the design of vaccines and immunotherapies. Measurement of cytotoxic
T lymphocyte activity requires that the test antigen is presented by target cells having the same or
compatible class I major hystocompatibility complex antigens as the effector cells. Conventional
assays use target cells labeled with 51chromium and infer cytotoxic T lymphocyte activity by
measuring the isotope released by the target cells lysed following incubation with antigen-specific
cytotoxic T lymphocytes. This assay is sensitive but needs manipulation and disposal of hazardous
radioactive reagents and provides a bulk estimate of the reporter released, which may be influenced
by spontaneous release of the label and other poorly controllable variables. Here we describe a
novel method for producing target in outbred hosts and assessing cytotoxic T lymphocyte activity
by flow cytometry.
Results: The method consists of culturing skin fibroblasts, immortalizing them with a replication
defective clone of simian virus 40, and finally transducing them with a bicistronic vector encoding
the target antigen and the reporter green fluorescent protein. When used in a flow cytometry-
based assay, the target cells obtained with this method proved valuable for assessing the viral
envelope protein specific cytotoxic T lymphocyte activity in domestic cats acutely or chronically
infected with feline immunodeficiency virus, a lentivirus similar to human immunodeficiency virus
and used as animal model for AIDS studies.
Conclusion: Given the versatility of the bicistronic vector used, its ability to deliver multiple and
large transgenes in target cells, and its extremely wide cell specificity when pseudotyped with the
vesicular stomatitis virus envelope protein, the method is potentially exploitable in many animal
species.
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Background
Cytotoxic T lymphocytes (CTLs) are key components of
the cell-mediated immune responses and play an essential
role in protection from and containment of a variety of
pathogens [1]. Since CTLs have been shown to play a
major role in the control of human immunodeficiency
virus (HIV) and other lentiviruses [2,3], measurement of
their activity has become an important parameter for test-
ing the efficacy of candidate vaccines and other immuno-
logic interventions directed against these important
agents of disease [4].
CTL assays require that the test antigen is presented by tar-
get cells having the same or compatible class I major hys-
tocompatibility complex antigens as the effector cells.
This permits to the antigen-specific CTLs to interact with
the target cells and determine their lysis, which is then
quantitated as a measure of CTL activity. The most used
format is the 51chromium (51Cr)-release assay in which
this radioisotope, absorbed by the target cells prior to mix-
ing with the effector cells, is released in the supernatant
medium and measured at the end of the incubation
period [5]. This assay is sensitive but has the disadvantage
of requiring the manipulation and disposal of hazardous
radioactive reagents. Thus, over the years, 51Cr has been
tentatively replaced by various cell dyes with somewhat
inconsistent results. However, all these assays have the
limitation of providing a bulk estimate of the reporter
released, which may be influenced by several, poorly con-
trollable variables, such as inefficient labeling of target
cells or spontaneous release of the label [6]. More
recently, new flow cytometry-based (F-CTL) assays, using
target cells labeled with fluorescent dyes or substrates for
caspases or other apoptotic enzymes, have been proposed
[7-12]. These assays appear to be as or more sensitive than
the standard 51Cr methods and, in addition, may permit
to precisely count the target cells that have actually been
lysed and to identify the phenotype of the effector cells
involved [6,9].
Here, we describe a novel method for producing target
cells that has provided satisfactory results in an F-CTL
assay we have set up to assess envelope (Env)-specific CTL
activity in domestic specific pathogen-free (SPF) cats
infected with feline immunodeficiency virus (FIV), the
feline equivalent of HIV. Since no inbred cats are availa-
ble, testing CTL activity in this species is dependent on the
use of autologous target cells, a factor that has hitherto
limited routine measurements of CTL activity [13,14]. The
method relies on a bicistronic vector derived from FIV but
having very little left of the original virus which is used to
transduce immortalized feline skin fibroblasts. Since the
vector can be pseudotyped with the different Envs and
may have broad tropism [15], the method is potentially
exploitable in other animal species as well.
Results
Production and characterization of the target cells
Production of the target cells expressing the Env of FIV-
Petaluma (FIV-Pet) and reporter green fluorescent protein
(GFP) is schematically depicted by Figure 1. Primary
fibroblasts were obtained by culturing skin biopsies of the
study cats and, when confluent, transferred to larger
flasks. One flask was then used to control for cell compe-
tence for transfection by using a plasmid encoding GFP
(pcDNA3-GFP). As expected for primary cells and in
agreement with Köksoy et al. [16], the fibroblasts proved
moderately transfectable, since by day 2 post transfection
GFP expressing cells ranged between 15% and 30% (data
not shown). The remaining flasks were transfected with a
plasmid encoding a replication defective simian virus 40
(SV40) genome (pACTSV2) and subcultured every 3–4
days for further 3 weeks. Ten to 15 days later, the
pACTSV2 transfected cells showed unequivocal signs of
immortalization that were maintained for at least 30 pas-
sages regardless of whether the cells were kept in culture
continuously or repeatedly freeze-stored and cultured
again. This contrasted strongly with sister cultures that
were left untreated or transfected with pcDNA3-GFP,
which reached senescence after 6–8 passages and barely
resisted freezing (data not shown). Of note, fibroblasts
generated from FIV-infected animals – regardless of
whether immortalized or not – showed no evidence of FIV
replication, as determined by weekly testing the superna-
tants for p25 capsid antigen, suggesting that they had been
spared from infection or had stopped supporting detecta-
ble FIV replication as a result of culture (data not shown).
Transduction of pACTSV2 immortalized fibroblasts was
carried out with viral particles produced in 293T cells and
encapsidating the monocystronic vector carrying GFP
alone (vGFP) or the bicistronic version delivering Env and
GFP (vEnv-GFP) (Figure 1). For a preliminary assessment
of the efficiency of transduction, the immortalized fibrob-
lasts of an uninfected cat were exposed to serial 2-fold
dilutions of a vGFP preparation and, 2 days later, ana-
lyzed for GFP expression by flow cytometry. The propor-
tion of cells transduced proved clearly dose-dependent
ranging from 10% with 12.5 transduction units (TU)/cell
to over 90% with 200 TU/cell. Importantly, transduced
cells fluoresced at high levels (Figure 2A) even after several
weeks in culture and when repeatedly stored frozen and
recultured (data not shown), indicative of a stable trans-
duction. Different batches of the vectors and fresh or
thawed cells yielded similar results. Interestingly, for rea-
sons that were not specifically addressed, immortalized
fibroblasts proved consistently more prone to transduc-
tion (by a factor of approximately 5) than the non-
immortalized cells from which they derived (data not
shown).BMC Biotechnology 2009, 9:18 http://www.biomedcentral.com/1472-6750/9/18
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Unless differently stated, in the subsequent studies the
immortalized fibroblasts expressing Env and GFP
(Env+GFP+ fibroblasts) used as targets were obtained by
transducing with 100 TU vEnv-GFP per cell. Figure 2B
shows the results obtained with this TU dose in one exper-
iment in which we compared immortalized fibroblasts
obtained from 4 cats, one uninfected and 3 chronically
FIV infected, for susceptibility to transduction. Although
at day 2 post-transduction the percentage of control cells
expressing GFP alone (GFP+ fibroblasts) varied somewhat,
transduction was successful with the cells of all cats. In
addition, both the proportion of transduced cells and the
extent they expressed Env had a clear tendency to increase
with time, at least for the 3 weeks investigated (Figure 2C).
Importantly, the Env expressed by Env+GFP+ fibroblasts
showed a precursor to surface glycoprotein ratio similar to
that of cells chronically infected with FIV, indicating that
it was processed correctly (Figure 2C).
The Env+GFP+ fibroblasts as a stimulus for expanding Env-
specific CTL activity ex vivo
In this experiment we investigated if and how effectively
the Env+GFP+ fibroblasts could be used as a stimulus to
expand Env-specific CTL activity ex vivo by comparing
them with immortalized fibroblasts loaded with a pool of
peptides covering the whole FIV Env. This was done by
using the peripheral blood mononuclear cells (PBMCs) of
BR, BS and CF, 3 chronically FIV infected cats known to
possess substantial Env-specific CTL activity as a result of
boosting with a DNA immunogen (see below). These
PBMCs were co-cultured for 5 days with autologous
immortalized fibroblasts that had been transduced with
vEnv-GFP or had been pulsed for 1 hour with the pooled
peptides or, as controls, with autologous GFP+ fibroblasts
or fibroblasts that had not been further manipulated. The
PMBCs thus incubated were then tested for CTL activity
against Env+GFP+ fibroblasts. Lysis by PBMCs restimu-
lated with autologous GFP+ fibroblasts or immortalized
fibroblasts was at background levels (data not shown).
The Env+GFP+ fibroblasts caused an expansion of CTL
activity readily measurable (Figure 3A) and substantially
higher than the peptide-loaded counterparts (Figure 3B).
As expected, either stimulus had no effect on the PBMCs
of an uninfected cat used as control.
The Env+GFP+ fibroblasts as targets for measuring Env-
specific CTL activity in acutely FIV infected cats
Collectively, the above data had demonstrated that the
Env+GFP+ fibroblasts expressed the target and reporter
genes in stable and correct fashion. To test whether they
Outline of target cell production Figure 1
Outline of target cell production. Primary feline fibroblasts were immortalized by transfection with plasmid pACTSV2, an 
SV40 genome encoding a functional small T antigen and an internally deleted large T antigen. The cells thus immortalized were 
then transduced with vesicular stomatitis virus glycoprotein G (VSV-G) pseudotyped particles produced in 293T cells and 
delivering target env gene and reporter GFP gene.BMC Biotechnology 2009, 9:18 http://www.biomedcentral.com/1472-6750/9/18
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were also suitable targets for CTL assays, we employed
them in the F-CTL assay using, as effector cells, PBMCs
collected from cats during acute FIV infection. Fibroblasts
were harvested from SPF cats GN, GO, GP and GQ, proc-
essed as above, and frozen. The animals were then inocu-
lated with a dose of FIV-Pet which produced the expected
levels of viremia as determined starting 2 weeks post-
infection. CTL activity was examined 2, 4, 8 and 12 weeks
after infection. The test was carried out both with fresh
PBMCs and with PBMCs that, prior to the F-CTL assay,
were restimulated ex vivo with autologous Env+GFP+
fibroblasts as described above. Target cells were autolo-
gous Env+GFP+ fibroblasts and, as controls, autologous
GFP+ fibroblasts and heterologous Env+GFP+ fibroblasts;
however, significant cell lysis was observed only with the
former cells. As depicted by Figure 4, which shows the per-
cent specific lysis values observed with the unstimulated
PBMCs at effector:target (E:T) ratios of 1:10 and 1:50, in
one cat CTL activity could already be detected 2 weeks
post-infection. In the other animals, the test was first
Efficiency and duration of transduction of immortalized feline fibroblasts by vGFP and vEnv-GFP Figure 2
Efficiency and duration of transduction of immortalized feline fibroblasts by vGFP and vEnv-GFP. A: GFP expres-
sion by the fibroblasts of uninfected cat BO 2 days post-transduction with vGFP (50 TU/cell), as determined by flow cytometry. 
Left panel, percent GFP positive cells; middle panel, intensity of GFP expression; right panel, mock-transduced cells. B: Suscep-
tibility of fibroblasts from 3 FIV chronically infected cats and 1 uninfected cat to transduction by vEnv-GFP at 100 TU/cell. Per-
cent GFP positive cells (upper panel) and extent of Env expression (lower panel) were evaluated 2 days post-transduction by 
flow cytometry and western blot, respectively. C: GFP expression (upper panel) and Env expression (lower panel) by fibrob-
lasts of one infected cat (BS) transduced with vEnv-GFP at 50 TU/cell, evaluated at the indicated times by flow cytometry and 
western blot, respectively. The arrows in panels B and C indicate the Env precursor (135 Kd) and surface (95 Kd) glycopro-
teins. Bars represent SD calculated from 3 independent experiments. FL-4: Env expressed by the chronically FIV infected cell 
line FL-4.BMC Biotechnology 2009, 9:18 http://www.biomedcentral.com/1472-6750/9/18
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found positive at 4 weeks post-infection, usually at the E:T
ratio 50:1 only. At later times of infection, this picture did
not change significantly, except for the fact that E:T ratio
10:1 yielded a measurable level of lysis more frequently
than at earlier times. Percent lysis obtained with ex vivo
restimulated PBMCs were only marginally higher than
obtained with fresh PBMCs (data not shown), suggesting
that in acutely infected cats Env-specific CTL activity can-
not be significantly expanded ex vivo. Of note, cat GQ who
exhibited the most prompt and robust CTL response
developed levels of plasma viremia, proviral DNA in the
PBMC, and a reduction of circulating CD4+ T-lymphocyte
counts similar to the other animals (data not shown).
The Env+GFP+ fibroblasts as targets for measuring Env-
specific CTL activity in chronically FIV infected cats
In these experiments, Env+GFP+  fibroblasts and F-CTL
assay were used to measure anti-Env CTL in the PBMCs of
three SPF cats infected with FIV-Pet 5 years earlier. As
determined by periodical monitoring, these animals were
Flow cytometry plot of the CTL assay and comparative efficiency at restimulating CTL activity in vitro of Env transduced and  Env peptides loaded immortalized fibroblasts Figure 3
Flow cytometry plot of the CTL assay and comparative efficiency at restimulating CTL activity in vitro of Env 
transduced and Env peptides loaded immortalized fibroblasts. A: CTL activity following lymphocyte restimulation 
with Env-transduced immortalized fibroblasts as measured by F-CTL. Right and left panels show the results obtained with cats 
BR and BS, respectively. The gray line indicates the target population incubated alone, the thick line indicates residual target 
cells after incubation with restimulated lymphocytes. B: Comparative efficiency of Env transduced and Env peptides-loaded 
immortalized fibroblasts at restimulating CTL activity. Prior to the assay, the effector cells (PBMCs of chronically FIV infected 
cats boosted with p-Env-GMCSF 18 weeks earlier) were restimulated with Env+GFP+ fibroblasts (solid columns) or immortal-
ized fibroblasts pulsed for 1 hour with pooled peptides covering the entire Env (empty columns).BMC Biotechnology 2009, 9:18 http://www.biomedcentral.com/1472-6750/9/18
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in a steady state phase of infection since they had stable or
slightly fluctuating moderate levels of viremia, high FIV
antibodies titers, and moderately reduced circulating
CD4+ T-lymphocytes counts (data not shown). A fourth
cat (BO), who had been inoculated exactly as the others
but had remained consistently FIV negative, was used as
noninfected control. Effector PBMCs were either used
fresh or restimulated ex vivo by co-cultivation with autol-
ogous Env+GFP+ fibroblasts; however, in no case they
exhibited measurable CTL activity (time -8 weeks in Fig-
ure 5). An attempt was therefore done to boost anti-Env
immune responses of the cats by DNA immunization.
Starting 2 weeks after the above CTL assay, the 4 animals
were given 3 doses of a plasmid encoding the Env of FIV-
Pet and feline granulocyte-macrophage-colony stimulat-
ing factor (p-Env-GMCSF), 3 weeks apart, and after 2 fur-
ther weeks again tested for CTL activity. As shown by
Figure 5, the uninfected control cat showed no evidence
that this immunization had elicited significant CTL activ-
ity. In contrast, all 3 FIV chronically infected animals
exhibited robust CTL activity, ranging between 16% and
35% at E:T ratio 10:1. When the test was repeated 18 and
20 weeks after completion of DNA immunization, CTL
activity was found to have substantially declined; how-
ever, it was generally in the measurable range (Figure 5)
and, at least at week 18, it could be substantially expanded
ex vivo (Figure 3). Incidentally, this immunization was
also followed by a reduction of FIV RNA and proviral
DNA loads and by an increment of circulating CD4 T+
lymphocytes, thus showing that it had exerted a beneficial
effect on infection course (Pistello et al., manuscript in
preparation).
Discussion
Measurement of CTL activity is considered of paramount
importance for predicting protection from infection by
lentiviruses and other pathogens [1,3,4] but may be diffi-
cult due to a number of technical complications. In partic-
ular, production and use of suitable target cells generally
needs expertise and facilities for using vaccinia vectors and
radioactive compounds and, in non syngeneic hosts, it
may be especially tricky due to the need for a constant
source of MHC class 1 matched antigen-positive targets.
In developing the CTL assay described here we took
advantage of the method described by Kölsoy et al. [16]
who, as target cells, used immortalized autologous feline
primary fibroblasts infected with a recombinant vaccinia
vector delivering the test antigen. Similarly infected pri-
mary feline fibroblasts have also been used as target cells
but could be propagated in vitro for maximum 1–2
months before undergoing senescence and eventually
dying off [17-19]. In their study, Kölsoy et al. demon-
strated that it is possible to obtain an unlimited source of
Env-specific CTL activity in acutely FIV infected cats Figure 4
Env-specific CTL activity in acutely FIV infected cats. 
The PBMCs were obtained at the indicated times post-infec-
tion and used as effector cells without ex vivo restimulation. 
The dotted line indicates the cut-off value. Cat GP died 40 
days post inoculation due to unexplained renal failure.
Env-specific CTL activity in chronically FIV infected cats  before and after boosting with a DNA immunogen Figure 5
Env-specific CTL activity in chronically FIV infected 
cats before and after boosting with a DNA immuno-
gen. The effector PBMCs were obtained at the indicated 
times and used at E:T ratio 10:1 after ex vivo restimulation 
with Env+GFP+ fibroblasts. The dotted line indicates the cut-
off value.BMC Biotechnology 2009, 9:18 http://www.biomedcentral.com/1472-6750/9/18
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target cells retaining the same MHC class I phenotype as
the cells of origin by immortalizing fibroblasts with repli-
cation competent SV40. To avoid full transformation and
minimize the risk of abnormal self-antigen expression, we
have instead used a molecular clone of SV40, rendered
unable to replicate through an internal deletion in the
large T-antigen, which immortalized primary feline
fibroblasts as efficiently as wild-type SV40 (data not
shown). This clone had previously been shown to trans-
form established cell lines, such as NIH-3T3 cells, but to
be unable to transform primary rat embryo fibroblasts
[20-22].
Because we wished to test immortalized fibroblasts as a
tool for measuring Env-specific CTL activity in FIV
infected and vaccinated cats, we attempted to infect these
cells with FIV, with no success. Fibroblasts from FIV
infected cats also proved consistently virus-negative, thus
excluding the possibility of using direct FIV infection as a
means of obtaining the desired target cells. We therefore
exploited a bicistronic vesicular stomatitis virus glycopro-
tein G (VSV-G) coated vector derived in our laboratory
from FIV but carrying very little of the original virus, vec-
tor that had been previously shown to effectively intro-
duce transgenes into primary cells of both feline and
nonfeline origin [15]. The vector used carried the Env of
FIV-Pet and GFP as target and reporter transgene, respec-
tively. Immortalized fibroblasts transduced at high multi-
plicity with this vector were approximately 90% positive
for both transgenes and proved valuable both as target
cells for use in a F-CTL assay and as a stimulus for expand-
ing CTLs ex vivo.
Differently from the methods that rely on vaccinia virus
infection or transfection or on peptide loading used in tra-
ditional  51Cr assays [5,6] and in the more recently
described (F-CTL) assays [7-12], this method generates
target cells stably expressing the antigen of interest and the
reporter molecule. This has been achieved by using a bicis-
tronic vector that i) does not require the containment pro-
cedures needed for the recombinant vaccinia viruses that
are frequently used to introduce transgenes in target cells,
ii) overcomes the intrinsic resistance to transfection of pri-
mary and non-adherent cells, iii) delivers two large trans-
genes for up to 7 Kbs, iv) stably transduces cells, thus
permitting to use the same batch of targets in follow-up
studies, minimizing inter-assay variation, v) allows trans-
duction of cells irrespective of animal species; vi) is repli-
cation incompetent, making it unnecessary ultraviolet
irradiation or other treatments of the target cells to pre-
vent infection transmission to effector cells, and last but
not least, vii) permits the use of F-CTL assays. While most
other CTL assays detect radioisotopes or cell dyes released
from the target cell population in bulk and may have a
high background noise due to spontaneous release of the
markers, F-CTL assays rely on the actual enumeration of
target cells made fluorescent by GFP, a protein that is not
secreted by the cells and does not fluoresce if degraded or
improperly folded in dying cells, and with the use of spe-
cific cell-specific markers may also permit phenotyping of
the effector cells [6,9].
A limitation of the present study is that the F-CTL assay
was not directly compared to established techniques.
However, its validity was assessed by evaluating FIV Env-
specific CTL activity in both acutely and chronically FIV-
infected cats. The method proved valuable in either situa-
tion. During the early stages of infection, characterized by
acute viral replication and vigorous cell-mediated
immune responses [18,23], the assay detected levels of
Env-specific CTL activity in the PBMCs of infected cats
similar to those previously reported with 51Cr CTL assays
using SV40-immortalized or primary feline fibroblasts
infected by recombinant vaccinia viruses [18,24], with no
need for the effector cells to be restimulated ex vivo, a pro-
cedure frequently necessary when using the standard Cr51
assay [25]. In contrast, in the chronically infected cells we
detected no measurable Env-specific CTL activity even
when the effector PBMCs were restimulated ex vivo. This
may have reflected the fact that, especially in the periphery
[18], anti-FIV Env cell-mediated immune responses tend
to wane with time of infection [26-28], or immunosenes-
cence of the cats who were 10 year-old when tested [29],
or a combination of these factors [30]. In any case, admin-
istration to the chronically infected cats of a DNA vaccine
encoding the Env of the infecting FIV and feline granu-
loyte macrophage-colony stimulating factor (GM-CSF), a
cytokine known to induce dendritic cell proliferation and
improve antigen presentation [31], with a protocol that
had elicited fairly good cell-mediated immune responses
when tested in a prior prophylactic study (Pistello et al.,
manuscript in preparation), brought back substantial lev-
els of CTL activity. CTL activity showed a maximum 2
weeks after completion of the vaccination schedule and
then gradually decreased as previously observed for other
FIV antigens [18,25], but in 2/3 animals it remained
detectable for at least 20 weeks without the need for res-
timulating ex vivo their PBMC. Interestingly, this corre-
lated with a beneficial effect of the vaccine on infection
course, as demonstrated by a decrease of viral RNA in
plasma and proviral load in the PBMCs and an increase of
circulating CD4+ T-lymphocytes (Pistello, manuscript in
preparation). Of note, vaccination on an uninfected con-
trol cat elicited a modest CTL response that exceeded the
cut-off only at an early post-vaccination time point only,
suggesting that the vigorous CTL activity brought forth by
vaccination in the chronically infected cats was mostly
due to a recall of pre-existing immunity rather than to ex
novo induction.BMC Biotechnology 2009, 9:18 http://www.biomedcentral.com/1472-6750/9/18
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Conclusion
The F-CTL assay described, using immortalized feline
fibroblasts stably transduced with the test antigen and the
GFP reporter as target cells, has proven valuable in evalu-
ating Env-specific CTL activity in FIV infected and vacci-
nated cats. Given the versatility of the bicistronic vector
used for producing target cells, the method has the poten-
tial to be used for a wide array of antigens and hosts.
Methods
Plasmids and vectors
The GFP encoding plasmid pcDNA3-GFP was previously
described [25]. Plasmid pACTSV2 encoding a replication
defective SV40 genome with a functional small T and a
large T antigen mutated by an internal deletion of 43
amino acids [20] was a kind gift of Dr. Mauro Tognon
(University of Ferrara, Italy). Construction of the bicis-
tronic vEnv-GFP and monocystronic vGFP vectors,
derived from molecular clone p34TF10 of FIV-Pet, and of
the packaging (pΔenv1) and VSV G-protein (pVSV-G)
plasmids has been described [15]. Briefly, vEnv-GFP deliv-
ers the target Env of FIV-Pet and the reporter GFP placed
under the control of the FIV LTR and the cytomegalovirus
promoter, respectively (Figure 1). vGFP has the same
architecture except that it encodes the reporter alone.
Pseudotyped vector particles were generated in human
epithelial 293T cells that were co-transfected with pΔenv,
pVSV-G and either vEnv-GFP or vGFP, exactly as described
[15]. Two days later, approximately 80% of the cells were
GFP positive by FACS analysis, regardless of whether
exposed to vEnv-GFP or vGFP. The pseudotyped virus
preparations used for transduction consisted of 293T cell
culture supernatants harvested on day 2, filtered through
a 0.45 μm filter (Nalge Europe, Neerijse, Belgium), and
titered for TU in 293T cells as described [15]. They were
either used immediately or stored in aliquots at -80°C
until use, with no appreciable differences in transduction
efficiency.
Animals
The SPF cats (IFFA Credo, Lyon, France) used were housed
individually in our climatized animal facility in accord-
ance with European Community guidelines, had ad libi-
tum access to fresh water and a proprietary brand of cat
food, and were sedated with ketamine/diazepam intra-
muscularly prior to any procedure. Cats GN, GO, GP and
GQ were FIV infected after entering the study (acutely
infected cats). Infection was performed intraperitoneally
when 18-month old with 1 ml of a stock of pooled plasma
from FIV-Pet infected cats diluted to contain 10 cat infec-
tious doses 50% per ml. Three further cats (BR, BS and CF)
were already infected when the study started (chronically
infected cats). These had been infected exactly as above 5
years earlier and were 10-year old at the start of the study.
An additional 10-year old cat (BO) that had been simi-
larly inoculated but had escaped infection by all parame-
ters served as uninfected control for the latter animals.
Because the chronically infected cats showed no detecta-
ble Env-specific CTL activity (see below), they were
boosted by DNA immunization with p-Env-GMCSF, a
plasmid expressing the Env of FIV-Pet and feline GM-CSF,
as an immunoadjuvant (Pistello et al., manuscript in
preparation). This was inoculated intramuscularly at
doses of 300 μg (300 μl) into both hind legs (150 μl/site)
20 minutes after rubbing the shaved skin with Aldara
(Graceway Pharmaceuticals, Bristol, TN, USA), a topical
Imiquimod containing cream known to exert an adjuvant
effect. Infection of cats was monitored as described [25]
by testing for presence and loads of FIV RNA in plasma
and proviral DNA in the PBMCs, anti-FIV antibody in
serum and counting peripheral CD4+ and CD8+ T-lym-
phocyte.
Preparation of target cells
Primary fibroblasts were obtained from skin biopsies of
the study cats with sterile, 4 mm diameter, disposable skin
biopsy punches (Steifel Laboratories, Segrate, Italy) and
cultured in 6-well plates with minimum essential
medium-α (Sigma-Aldrich, Milan, Italy) supplemented
with ribonucleosides and deoxyribonucleosides, 10%
fetal bovine serum (FBS; Sigma-Aldrich), 200 U/ml peni-
cillin and streptomycin (Eurobio, Labtek, Milan, Italy)
and 2 mM L-glutamine (Sigma-Aldrich). Around day 20,
when the cultures were confluent, the cells were immor-
talized by transfecting 4–5 × 104 cells, seeded the day
before in 10 cm Petri dishes, with 2 μg pACTSV2 [20,21]
and using a calcium phosphate method previously
described [15]. This led to the appearance of typical signs
of cell immortalization (i.e. unlimited replication, loss of
inhibition contact and growth in low FBS medium) in
approximately one week and to generalized immortaliza-
tion in 10 to 15 days. The fibroblasts thus immortalized
were then seeded into 6-well plates at 3 × 105 cells/well
and, 18 hours later, transduced with 3 × 106 TU of vEnv-
GFP (Env+GFP+ fibroblasts) or, as antigen control, with a
similar dose of vGFP (GFP+ fibroblasts). Expression of the
transgenes was monitored 2 days post-transduction and
then twice weekly for up to 4 weeks by flow cytometry
(GFP) and Western blot (Env). Finally, the target cells
were expanded and frozen for further use.
Analysis of the target cells for Env expression
Env expression by the target cells was evaluated by West-
ern blot analysis. Briefly, 1 × 105 cells were lysed in 100 μl
lysis buffer (10 mM Tris-HCl pH 7.5, 150 mM NaCl, 2
mM EDTA, 0.5% Nonidet P-40), mixed with 2× loading
buffer, and loaded (20 μl) on a 10% polyacrylamide gel
(Bio-Rad Laboratories, Milan, Italy). Proteins were trans-
ferred onto a nytran C-extra nitrocellulose membrane
(General Electric Healthcare, Milan, Italy) and reactedBMC Biotechnology 2009, 9:18 http://www.biomedcentral.com/1472-6750/9/18
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with the anti-FIV surface glycoprotein monoclonal anti-
body vpg71.2, kind gift of Dr. Brian Willett, University of
Glasgow, Glasgow, UK. Detection was done with a rabbit
anti-mouse IgG horseradish peroxidase-conjugated mon-
oclonal antibody (Sigma-Aldrich). The FIV chronically
infected feline lymphoid cell line FL-4 [32] was used as
positive control.
Effector cells
Effector cells were PBMCs separated from 20 ml of EDTA
or citrate anticoagulated blood of the study cats on Ficoll/
Hystopaque 1077 (Sigma-Aldrich), washed in PBS, viabil-
ity counted with trypan blue, and suspended in RPMI
1640 (Sigma Aldrich) supplemented with 2 mM L-
glutamine, 200 U/ml penicillin and streptomycin and
10% FBS. PBMCs were used as such or after ex vivo restim-
ulation. For restimulation, 5 × 106 PBMCs were cultured
in RPMI 1640 supplemented as above in 6-well plates that
had been seeded with 1 × 105 Env+GFP+ or, as a negative
control, GFP+ fibroblasts 1 day earlier. After partial substi-
tution of the culture medium with fresh medium contain-
ing 20 U/ml human interleukin-2 (Roche Diagnostics,
Milan Italy) at day 3, the restimulated cells were harvested
on day 5, viability counted, and suspended as above. In
one experiment, restimulation was also carried out by
incubating the PBMCs with immortalized fibroblasts that
had been loaded for 1 hour with 10 μM (final concentra-
tion) pooled 21-mer peptides overlapping by 11 amino
acids and encompassing the entire sequence of the FIV-Pet
Env. The peptides had been synthesized by Espikem (Flor-
ence, Italy) with fmoc chemistry and were >95% pure.
F-CTL assay
The day before the assay, 1 × 104 Env+GFP+ fibroblasts
and, as negative control, GFP+ fibroblasts derived from at
least two distinct cats were individually seeded onto a 48-
well plate and incubated overnight to allow complete
adherence. PBMCs, either freshly separated or restimu-
lated in vitro, were added at E:T ratios of 10:1 and 50:1
onto autologous and heterologous fibroblasts. After over-
night incubation at 37°C in a humidified CO2 atmos-
phere, the PBMCs were removed, and the adherent cells
extensively washed, trypsinized and fixed for FACS analy-
sis. Analysis was performed using a FACScan cytometer
(Becton Dickinson). The forward scatter (FSC) threshold
was set to measure nonviable cells as well and to acquire
1 × 106 events/sample. Cellular debris were then left out
by gating in FSC-SSC dot plots during data acquisition.
Numbers of viable fluorescent cells were plotted in a
number of events/fluorescence intensity (FL-1) histo-
gram, and acquired data were analyzed using CellQuest
Pro software (version 3.4). Samples were analyzed in trip-
licate and percent specific anti-Env CTL activity was calcu-
lated using the formula: (% fluorescent target cells
incubated alone - % fluorescent target cells incubated with
autologous effector cells) - (% fluorescent target cells incu-
bated alone - % fluorescent target cells incubated with het-
erologous effector cells)/% fluorescent target cells
incubated alone × 100. In preliminary studies aimed at
evaluating nonspecific target cell lysis, PBMCs were also
incubated with autologous and heterologous GFP+ posi-
tive cells. Nonspecific lysis (background), calculated using
cat BR, BS, CF, and BO cells in three independent experi-
ments, averaged 2.9%, and standard deviation (SD) was
1.0. Thus, values of lysis above 6% (i.e. background + 3 ×
SD) were considered positive.
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